BLFS Biolife Solutions Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BLFS

Price (delayed)

$21.53

Market cap

$920.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.49

Enterprise value

$937.52M

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage ...

Highlights
The company's revenue has surged by 60% YoY and by 4.7% QoQ
The company's gross profit rose by 18% YoY and by 12% QoQ
BLFS's gross margin is down by 26% year-on-year but it is up by 6% since the previous quarter
BLFS's quick ratio is up by 9% since the previous quarter but it is down by 4.1% year-on-year
The debt has surged by 70% since the previous quarter and by 55% year-on-year
The equity has contracted by 17% YoY
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.biolifesolutions.com
Peers: REX AMRS

Key stats

What are the main financial stats of BLFS
Market
Shares outstanding
42.77M
Market cap
$920.75M
Enterprise value
$937.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.25
Price to sales (P/S)
5.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.06
Earnings
Revenue
$154.81M
EBIT
-$111.09M
EBITDA
-$92.02M
Free cash flow
-$27.87M
Per share
EPS
-$2.49
Free cash flow per share
-$0.65
Book value per share
$9.58
Revenue per share
$3.63
TBVPS
$4.43
Balance sheet
Total assets
$487.68M
Total liabilities
$79.43M
Debt
$43.84M
Equity
$408.25M
Working capital
$98.93M
Liquidity
Debt to equity
0.11
Current ratio
3.68
Quick ratio
2.55
Net debt/EBITDA
-0.18
Margins
EBITDA margin
-59.4%
Gross margin
29.7%
Net margin
-67.1%
Operating margin
-73.7%
Efficiency
Return on assets
-20.2%
Return on equity
-23.3%
Return on invested capital
-88.6%
Return on capital employed
-24.6%
Return on sales
-71.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLFS stock price

How has the Biolife Solutions stock price performed over time
Intraday
0.05%
1 week
0.05%
1 month
-5.28%
1 year
-2.23%
YTD
18.3%
QTD
18.3%

Financial performance

How have Biolife Solutions's revenue and profit performed over time
Revenue
$154.81M
Gross profit
$46.02M
Operating income
-$114.11M
Net income
-$103.83M
Gross margin
29.7%
Net margin
-67.1%
The company's revenue has surged by 60% YoY and by 4.7% QoQ
BLFS's gross margin is down by 26% year-on-year but it is up by 6% since the previous quarter
The company's gross profit rose by 18% YoY and by 12% QoQ
BLFS's net income is down by 11% since the previous quarter

Growth

What is Biolife Solutions's growth rate over time

Valuation

What is Biolife Solutions stock price valuation
P/E
N/A
P/B
2.25
P/S
5.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.06
The EPS has declined by 10% since the previous quarter
BLFS's price to book (P/B) is 59% lower than its 5-year quarterly average of 5.5 and 2.2% lower than its last 4 quarters average of 2.3
The equity has contracted by 17% YoY
The company's revenue has surged by 60% YoY and by 4.7% QoQ
The P/S is 55% lower than the 5-year quarterly average of 13.3 and 19% lower than the last 4 quarters average of 7.3

Efficiency

How efficient is Biolife Solutions business performance
The ROE has contracted by 15% from the previous quarter
Biolife Solutions's return on assets has decreased by 15% QoQ
The ROIC has grown by 9% from the previous quarter

Dividends

What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLFS.

Financial health

How did Biolife Solutions financials performed over time
The total liabilities has increased by 37% from the previous quarter and by 13% YoY
The total assets has decreased by 13% YoY but it has increased by 3.7% QoQ
The debt is 89% smaller than the equity
Biolife Solutions's debt to equity has soared by 83% from the previous quarter and by 83% YoY
The debt has surged by 70% since the previous quarter and by 55% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.